Filing summary
Entity discrepancy: The request identifies Bio Green Med Solution, Inc., but the supplied filing is Cyclacel Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2011. This summary reflects the supplied filing, not Bio Green Med Solution.
Business context and reporting period
Cyclacel is a development-stage biopharmaceutical company focused on cancer drugs. Its lead candidate, sapacitabine, entered the pivotal Phase 3 SEAMLESS trial for elderly patients with newly diagnosed acute myeloid leukemia (AML); the company also markets three products in the United States. Financial results cover the three and six months ended June 30, 2011, compared with 2010.
Financial results and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $0.168 million (2010: $0.119 million) | $0.360 million (2010: $0.389 million) |
| Operating loss | $3.797 million (2010: $4.386 million) | $8.597 million (2010: $8.833 million) |
| Net loss | $3.552 million (2010: $3.933 million) | $8.140 million (2010: $9.040 million) |
| Net loss applicable to common shareholders | $3.734 million (2010: $6.543 million) | $8.504 million (2010: $12.358 million) |
| Basic and diluted loss per share | $0.08 (2010: $0.18) | $0.18 (2010: $0.36) |
| Operating cash used | Not separately reported | $8.456 million in the cash flow statement (2010: $9.776 million) |
Product revenue was $0.168 million for the quarter and $0.360 million for the half year. Six-month cost of goods sold was $0.178 million, or 49% of product revenue; quarterly cost of goods sold was $0.072 million, or 43% of product revenue. These product-level figures do not represent an overall company gross margin.
At June 30, 2011, cash and cash equivalents were $20.614 million, down $8.881 million from year-end 2010. Working capital was $16.409 million, versus $24.516 million at year-end. Total liabilities were $6.040 million, all classified as current; the balance sheet reports no debt. Preferred stock had an aggregate liquidation preference, including undeclared cumulative dividends, of approximately $13.345 million. Accumulated development-stage deficit was approximately $249.961 million.
The company reported no investing cash flows in the first half of 2011. Financing used $0.441 million, including a $0.364 million preferred-stock dividend. Management’s liquidity discussion gives operating cash use as $8.477 million, while the cash flow statement reports $8.456 million; the filing text does not provide a clear reconciliation.
Material changes versus the prior comparable period
- Quarterly revenue rose 41%, largely because 2010 product revenue was reduced by product returns; collaboration revenue was nil in 2011.
- First-half revenue fell 7% as collaboration and grant revenue recorded in 2010 did not recur, partly offset by higher product revenue.
- First-half research and development expense rose 41% to $4.939 million, mainly from sapacitabine development, including a $1.6 million Daiichi Sankyo milestone and higher manufacturing and testing costs.
- First-half selling, general and administrative expense declined 30% to $3.840 million, principally reflecting lower professional costs, salaries, rent and stock compensation, partly offset by higher patent costs.
- First-half net loss narrowed, while the non-cash warrant revaluation shifted from a $0.516 million loss in 2010 to a $0.203 million gain in 2011.
Outlook, risks, contingencies and unusual items
- Management expected available funds, including proceeds from the July financing, to fund planned operations for at least 12 months. It also expected substantial future losses and higher 2011 R&D spending as SEAMLESS enrollment progressed. The company did not expect grant revenue for the remainder of 2011.
- On July 7, 2011, the company completed an offering of 7,617,646 common shares and warrants for approximately $10.4 million gross and $9.3 million net proceeds. The offering provides liquidity but dilutes existing shareholders and includes warrants exercisable at $1.36 per share.
- On July 11, Daiichi Sankyo waived a sapacitabine-license termination right tied to obtaining regulatory approval by September 2011. In exchange, future royalties increase by 1.25%–1.50%, depending on sales. A $1.6 million milestone payment was made in July; further milestones of up to $9.3 million could become payable.
- On July 8, the board declined to declare the second-quarter 2011 preferred dividend. Multiple earlier quarterly dividends were also undeclared. Unpaid dividends accrue to the preferred liquidation preference; preferred holders elected two directors after the missed-dividend threshold was reached.
- Interim results from a Phase 1/2 sapacitabine-plus-decitabine study included a 34.8% overall response rate and all-cause mortality of 4.5% at 30 days and 9.5% at 60 days. These are interim results from a small study, not proof of efficacy or approval prospects.
- The SEAMLESS trial’s Special Protocol Assessment does not guarantee FDA approval. Clinical, regulatory, manufacturing, funding, competition, licensing and intellectual-property risks remain material. The company also disclosed litigation with Celgene over four romidepsin-related patents; Cyclacel counterclaimed for infringement and sought damages and injunctive relief.
- Management reported disclosure controls and procedures were not effective as of June 30 because previously identified material weaknesses remained. Remediation included hiring finance personnel and outside consultants; management cautioned that remediation would take time and add expense.
Most important facts for investors to verify
- Confirm the filing belongs to Cyclacel Pharmaceuticals, not the company named in the request.
- Check current cash runway against trial spending, the July offering proceeds, milestone payments and accrued preferred dividends.
- Track SEAMLESS enrollment, the DSMB review required before the randomized trial portion, and subsequent clinical and regulatory developments.
- Review the preferred stock’s cumulative unpaid dividends, liquidation preference and associated board-election rights.
- Assess progress in remediating the disclosed internal-control material weaknesses and any later reporting or restatement developments.
- Monitor the Celgene litigation, sapacitabine license obligations and the effect of the amended royalty terms.